Zai Lab Limited Share Price BOERSE MUENCHEN
Stocks
1ZL
US98887Q1040
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.10 EUR | -2.42% |
|
-8.33% | +10.74% |
| 30/06 | Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing | MT |
| 16/06 | Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug | MT |
| Market Cap | 205.72Cr 180.77Cr 168.73Cr 154.85Cr 289.87Cr 20TCr 297.02Cr 2TCr 782.48Cr 9.75TCr 772.38Cr 755.62Cr 34TCr | P/E 2026 * |
-8.16x | P/E 2027 * | -9.74x |
|---|---|---|---|---|---|
| Enterprise Value | 156.37Cr 137.4Cr 128.26Cr 117.71Cr 220.34Cr 15TCr 225.77Cr 1.52TCr 594.78Cr 7.41TCr 587.1Cr 574.36Cr 26TCr | EV / Sales 2026 * |
3.49x | EV / Sales 2027 * | 2.84x |
| Free-Float |
95.17% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Zai Lab Limited
| 1 week | -8.33% | ||
| 1 month | +5.77% | ||
| 3 months | -11.76% | ||
| 6 months | +13.01% | ||
| Current year | +10.74% |
| 1 week | 16.1 |  | 18 |
| 1 month | 15.6 | | 18.1 |
| 3 years | 12.8 | | 38.8 |
| 5 years | 12.8 | | 132 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ying Du
CEO | Chief Executive Officer | 61 | 01/04/2014 |
Ya jing Chen
DFI | Director of Finance/CFO | 58 | 07/07/2023 |
Rafael Amado
PSD | President | 62 | 01/12/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Ying Du
CHM | Chairman | 61 | 01/04/2014 |
John Diekman
BRD | Director/Board Member | 83 | 01/01/2017 |
Peter Wirth
BRD | Director/Board Member | 75 | 01/01/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.42% | -8.33% | -50.60% | -42.31% | 209.32Cr | |
| +0.03% | +6.79% | +24.59% | -6.79% | 7.07TCr | |
| +0.28% | +3.12% | +35.58% | +214.73% | 5.43TCr | |
| -4.52% | +47.90% | +47.90% | +47.90% | 4.93TCr | |
| -1.48% | +8.85% | -53.53% | -53.08% | 3.99TCr | |
| +1.76% | +5.81% | +63.59% | -21.11% | 3.04TCr | |
| -2.18% | +9.77% | +64.26% | +101.46% | 2.6TCr | |
| -2.36% | -6.16% | +66.84% | -54.08% | 2.21TCr | |
| +2.01% | -2.76% | -10.26% | +145.08% | 2TCr | |
| -2.35% | +1.06% | +80.35% | +142.71% | 1.68TCr | |
| Average | -1.24% | +2.63% | +26.87% | +47.45% | 3.66TCr | |
| Weighted average by Cap. | -1.12% | +3.67% | +30.19% | +52.52% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 45Cr 39Cr 37Cr 34Cr 63Cr 4.29TCr 65Cr 435.37Cr 170.26Cr 2.12TCr 168.07Cr 164.42Cr 7.33TCr | 59Cr 52Cr 49Cr 45Cr 84Cr 5.7TCr 86Cr 578.31Cr 226.16Cr 2.82TCr 223.24Cr 218.4Cr 9.74TCr |
| Net income | -24Cr -21Cr -20Cr -18Cr -34Cr -2.34TCr -35Cr -237.46Cr -93Cr -1.16TCr -92Cr -90Cr -4TCr | -16Cr -14Cr -13Cr -12Cr -22Cr -1.52TCr -23Cr -154.5Cr -60Cr -752.93Cr -60Cr -58Cr -2.6TCr |
| Net Debt | -49Cr -43Cr -40Cr -37Cr -70Cr -4.73TCr -71Cr -479.97Cr -187.7Cr -2.34TCr -185.28Cr -181.26Cr -8.09TCr | -37Cr -33Cr -30Cr -28Cr -52Cr -3.56TCr -54Cr -361.21Cr -141.26Cr -1.76TCr -139.44Cr -136.41Cr -6.09TCr |
| Date | Price | Change |
|---|---|---|
| 29/26/29 | €16.10 | -2.42% |
| 28/26/28 | €16.50 | +0.61% |
| 27/26/27 | €16.40 | -3.53% |
| 24/26/24 | €17.00 | -3.41% |
| 23/26/23 | €17.60 | -2.22% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ZLAB Stock
- 1ZL Stock
Select your edition
All financial news and data tailored to specific country editions
